Invex Therapeutics (ASX:IXC) ROE % Adjusted to Book Value : -14.02% (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics ROE % Adjusted to Book Value?

Invex Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -12.90%. Invex Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 0.92. Invex Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -14.02%.

Invex Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Invex Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics ROE % Adjusted to Book Value Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

ROE % Adjusted to Book Value

-3.84

-5.47

-9.96

-43.92

-15.44

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial						-17.42	-47.83	-27.47	21.71	-14.02

Competitive Comparison of Invex Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Invex Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Invex Therapeutics ROE % Adjusted to Book Value Calculation

Invex Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-12.20%	/	0.79
	=	-15.44%

Invex Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-12.90%	/	0.92
	=	-14.02%

Invex Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.